Key result
A review of natalizumab, alemtuzumab, and ocrelizumab presents updated data on their effectiveness and safety for treating highly active multiple sclerosis to guide therapy choices.
Why the study?
Aggressive multiple sclerosis features an atypical course with frequent exacerbations, rapid disability progression, and marked MRI activity, necessitating updated data on monoclonal antibody safety and efficacy.
What is the effectiveness and safety of monoclonal antibody drugs (natalizumab, alemtuzumab, ocrelizumab) in patients with highly active multiple sclerosis?
What is the effectiveness and safety of monoclonal antibody drugs (natalizumab, alemtuzumab, ocrelizumab) in patients with highly active multiple sclerosis?
The review summarizes effectiveness and safety data for natalizumab, alemtuzumab, and ocrelizumab in highly active multiple sclerosis to guide treatment decisions.
May inform monoclonal antibody selection in highly active MS; leaves open need for head-to-head trials.
The clinical course of multiple sclerosis (MS) is characterized by great variability. 'Aggressive' MS, a concept used in the last 10 years, is associated with atypical course of the disease, which is manifested by more frequent exacerbations, the rapid increase in disability and pronounced signs of radiological activity according to MRI. The review presents data on the effectiveness of three monoclonal antibody drugs - natalizumab, alemtuzumab and ocrelizumab. In addition, updated data on the safety of monoclonal antibodies are presented to help the physician make a balanced choice of a drug and therapy strategy.
No takes yet. Share an insight, caveat, or question.
Н. В. Хачанова (2019) conducted a review in highly active multiple sclerosis. natalizumab, alemtuzumab, and ocrelizumab was evaluated. A review of natalizumab, alemtuzumab, and ocrelizumab presents updated data on their effectiveness and safety for treating highly active multiple sclerosis to guide therapy choices.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: